A Phase 1/2 interventional study of Omacetaxine and Azacitidine in High Grade Myelodysplastic Syndromes, sponsored by University of Colorado, Denver. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by University of Colorado, Denver · Phase 1/2, Interventional, and Treatment
Cohort 0: De-Escalation Omacetaxine .5mg/m2 · Cohort 1: Escalation Phase Omacetaxine .75mg/m2 · Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 · Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 · Cohort 4: Expansion Phase Omacetaxine .5mg/m2 · Cohort 5: Relapse Phase
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 130 studies testing azacitidine in Myelodysplastic Syndromes — 13 open to participants now, 25 under way, 3 of them phase 3. Azacitidine · Myelodysplastic Syndromes.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, this one is the 79th largest by enrollment of the 126 interventional ones that give a count, is one of 5 that started in 2018, is one of 20 in phase 1/2, reaches primary completion later than 5 of the 24 other live ones, and was the 97th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.
Browse Myelodysplastic Syndromes studies →13 of the 130 studies testing azacitidine in Myelodysplastic Syndromes are open now, in 12 countries. Recruiting first, the newest first:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70
City of Hope Medical Center · Sites in United States
Ages 18–75
Medical College of Wisconsin · Sites in United States
Ages 18+
Institut de Recherches Internationales Servier · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Beijing 302 Hospital · Sites in China
Ages 18–70
By country, each count listing its studies:
Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
130 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 86 · Phase 3 12 · Phase 4 3
First in 2000; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 38 across the 126 interventional studies. Of the 88 that completed or were terminated, 42 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 130 have an industry lead sponsor. The 10 most frequent:
University of Colorado, Denver is the lead sponsor of 1,547 studies on the registry; 318 are open to participants now.
Of its 148 completed or terminated interventional studies of FDA-regulated products, 93 (63%) have results posted.
University of Colorado, Denver has 4 studies filed under Myelodysplastic Syndromes — fewer than ten, so there is no comparison to draw.
9 of the studies testing azacitidine in Myelodysplastic Syndromes that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06465953Phase 3Institut de Recherches Internationales ServierIvosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation | 2027-11-01 |
| NCT05788679Karolinska University HospitalA Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS | 2026-12 |
| NCT00392353National Cancer Institute (NCI)Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | 2026-12-31 |
| NCT06502145Medical College of WisconsinIadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 130 studies testing azacitidine in Myelodysplastic Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will treat patients with previously untreated high grade myleodysplastic syndromes (MDS) with both omacetaxine mepesuccinate and azacitidine.
This is an open-label, phase I/II study for previously untreated patients with high grade MDS using omacetaxine and azacitidine with a small expansion cohort for relapsed and refractory MDS patients. Phase I features dose escalation, where patients will be assigned to one of three cohorts to receive different doses of omacetaxine with the standard dose and schedule of azacitidine, over a 28 day cycle. Phase II features the maximum tolerated dose from the Phase 1 study. An additional expansion cohort of 10 MDS patients who have failed to respond to or responded and relapsed after at least one line of therapy containing a hypomethylating agent therapy will also be accrued.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A subject will be eligible for study participation if he/she meets the following criteria within 14 days prior to the first day of therapy (bone marrow can be performed 28 days prior to the first day of therapy).
Subject must have adequate liver function as demonstrated by:
Exclusion Criteria:
A subject will not be eligible for study participation if he/she meets any of the following criteria:
Subject has any history of condition(s) that in the opinion of the investigator would adversely affect his/her participating in this study including, but not limited to:
Subject has a history of other prior to study entry, except for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
De-escalation dose if DLTs are experienced for Cohort 1. Dose is Omacetaxine .5mg/m2 subcutaneous BID days 1-7.
Drug: Omacetaxine · Drug: Azacitidine
Patients in Cohort 1 will receive .75mg/m2 subcutaneous BID days 1-7.
Drug: Omacetaxine · Drug: Azacitidine
Patients in Cohort 2 will receive 1.0mg/m2 subcutaneous BID days 1-7.
Drug: Omacetaxine · Drug: Azacitidine
Patients in Cohort 3 will receive 1.25mg/m2 subcutaneous BID days 1-7.
Drug: Omacetaxine · Drug: Azacitidine
Dosing in Expansion Phase is based on the MTD determined with Cohorts 0-3. MTD was determined to be .5 mg/m2. Patients received .5mg/m2 Omacetaxine BID subcutaneously days 1-7.
Drug: Omacetaxine · Drug: Azacitidine
Drug: Omacetaxine · Drug: Azacitidine
Phase I is a dose escalation phase. Patients will be enrolled into one of three cohorts to receive omacetaxine subcutaneously (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
Also known as: Phase 1
Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
Also known as: Phase 1
Phase II is a maximum tolerated dose phase. Phase I will determine the maximum tolerated dose (highest amount that can be safely administered). Patients will receive omacetaxine subcutaneously at the maximum tolerated dose (0.5, 0.75, 1.0, or 1.25 mg/m2) twice daily on days 1 to 7.
Also known as: Phase 2
Azacitidine will be given at the standard dose and schedule, 75 mg/m2 once daily, on days 1 to 7. The patients will then be monitored for 21 more days ( to complete one 28 day cycle) but no more medication will be administered during those 21 days.
Also known as: Phase 2
Number of Participants Without Dose Limiting Toxicities in Cycle 1 for Phase 1 (Dose Escalation) Cohorts 0 and 1 to Determine Maximum Tolerated Dose
Determine the recommended dose of omacetaxine based on the maximum tolerated dose. The MTD is defined as the highest dose at which ≤1 patient experiences a DLT in Cycle 1. Count of participants who did not experience a DLT are listed in outcome measure data table.
Time frame: First treatment through end of Cycle 1 (28 days) only for dose escalation cohorts.
Overall Response Rate
This was a pre-specified primary outcome measure defined by the proportion of patients who achieve any category of complete remission (CR, includes CR and marrow CR) or partial remission (PR) based on the 2006 International Working Group (IWG) criteria for MDS1.
Time frame: First treatment date to study end date, or death, whichever comes first, up to 4 years.
Overall Survival
Overall survival will be defined as the amount of time from administration of the initial dose of omacetaxine and azacitidine to death from any cause.. This will be measured using Kaplan-Meier survival analysis curves.
Time frame: First treatment date to study end date, or death, whichever comes first, up to 4 years.
Progression Free Survival
Progression Free Survival will be defined as the amount of time from administration of the initial dose of omacetaxine and azacitidine that a patient lives with the disease but does not get worse. This will be measured using Kaplan-Meier survival analysis curves.
Time frame: First treatment date to study end date, or death, whichever comes first, up to 4 years.
Duration of Response
Duration of Response will be defined as Time from documentation of tumor response to disease progression.This will be measured using Kaplan-Meier survival analysis curves.
Time frame: First treatment date to study end date, or death, whichever comes first, up to 4 years.
| Milestone | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort |
|---|---|---|---|---|---|---|
| Started | 3 | 6 | 0 | 0 | 15 | 4 |
| Escalation phase (1) | 3 | 6 | 0 | 0 | 0 | 0 |
| Expansion phase (2) | 0 | 0 | 0 | 0 | 15 | 4 |
| Completed | 3 | 6 | 0 | 0 | 15 | 4 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
Determine the recommended dose of omacetaxine based on the maximum tolerated dose. The MTD is defined as the highest dose at which ≤1 patient experiences a DLT in Cycle 1. Count of participants who did not experience a DLT are listed in outcome measure data table.
| Participants | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort |
|---|---|---|---|---|---|---|
| Number of Participants Without Dose Limiting Toxicities in Cycle 1 for Phase 1 (Dose Escalation) Cohorts 0 and 1 to Determine Maximum Tolerated Dose | 1 | 5 | 0 | 0 | 0 | 0 |
This was a pre-specified primary outcome measure defined by the proportion of patients who achieve any category of complete remission (CR, includes CR and marrow CR) or partial remission (PR) based on the 2006 International Working Group (IWG) criteria for MDS1.
| Participants | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort |
|---|---|---|---|---|---|---|
| Overall Response Rate | 0 | 0 | 0 | 0 | 7 | 0 |
Overall survival will be defined as the amount of time from administration of the initial dose of omacetaxine and azacitidine to death from any cause.. This will be measured using Kaplan-Meier survival analysis curves.
| Days | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort |
|---|---|---|---|---|---|---|
| Overall Survival | NA (186 to NA) | 900 (112 to NA) | — | — | 279 (114 to 611) | — |
Progression Free Survival will be defined as the amount of time from administration of the initial dose of omacetaxine and azacitidine that a patient lives with the disease but does not get worse. This will be measured using Kaplan-Meier survival analysis curves.
| Days | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort |
|---|---|---|---|---|---|---|
| Progression Free Survival | NA (77 to NA) | 68 (40 to NA) | — | — | 45 (35 to 227) | — |
Duration of Response will be defined as Time from documentation of tumor response to disease progression.This will be measured using Kaplan-Meier survival analysis curves.
| Days | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort |
|---|---|---|---|---|---|---|
| Duration of Response | NA (109 to NA) | 444 (28 to NA) | — | — | 313 (73 to NA) | — |
Collected over Serious Adverse Events and Other (non-serious) Adverse Events will be documented from the time the patient receives the first dose of study drug until 30 days after last study treatment, an average of 60 days. All-cause mortality is documented through study completion, an average of 4 years.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | 3/3 (100%) | 3/3 (100%) | 3/3 (100%) |
| Cohort 0: De-Escalation Omacetaxine .5mg/m2 | 4/6 (66.7%) | 3/6 (50%) | 6/6 (100%) |
| Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | — | — | — |
| Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | — | — | — |
| Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | 10/15 (66.7%) | 13/15 (86.7%) | 15/15 (100%) |
| Cohort 5: Relapse Cohort | 1/4 (25%) | 2/4 (50%) | 4/4 (100%) |
| Event | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort |
|---|---|---|---|---|---|---|
| Febrile NeutropeniaBlood and lymphatic system disorders | 2/3 | 1/6 | — | — | 5/15 | 1/4 |
| Acute Kidney InjuryRenal and urinary disorders | 1/3 | 0/6 | — | — | 1/15 | 0/4 |
| Lung InfectionRespiratory, thoracic and mediastinal disorders | 1/3 | 0/6 | — | — | 0/15 | 0/4 |
| FeverGeneral disorders | 0/3 | 1/6 | — | — | 1/15 | 1/4 |
| SepsisInfections and infestations | 0/3 | 1/6 | — | — | 1/15 | 1/4 |
| Cardiac Disorders - OtherCardiac disorders | 0/3 | 0/6 | — | — | 0/15 | 1/4 |
| Intracranial HemorrhageNervous system disorders | 0/3 | 0/6 | — | — | 0/15 | 1/4 |
| Other, not specified in this listGeneral disorders | 0/3 | 1/6 | — | — | 0/15 | 0/4 |
| SinusitisInfections and infestations | 0/3 | 1/6 | — | — | 0/15 | 0/4 |
| Upper gastrointestinal hemorrhageGastrointestinal disorders | 0/3 | 1/6 | — | — | 0/15 | 0/4 |
| Event | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort |
|---|---|---|---|---|---|---|
| Chest Pain - CardiacCardiac disorders | 3/3 | 0/6 | — | — | 0/15 | 0/4 |
| AnemiaBlood and lymphatic system disorders | 1/3 | 5/6 | — | — | 7/15 | 1/4 |
| Platelet Count DecreasedInvestigations | 2/3 | 5/6 | — | — | 7/15 | 1/4 |
| White blood cell decreasedInvestigations | 2/3 | 5/6 | — | — | 7/15 | 0/4 |
| AnorexiaMetabolism and nutrition disorders | 2/3 | 2/6 | — | — | 2/15 | 1/4 |
| DiarrheaGastrointestinal disorders | 2/3 | 0/6 | — | — | 1/15 | 1/4 |
| Edema LimbsGeneral disorders | 2/3 | 1/6 | — | — | 2/15 | 1/4 |
| HypomagnesemiaMetabolism and nutrition disorders | 2/3 | 1/6 | — | — | 2/15 | 2/4 |
| Postnasal DripRespiratory, thoracic and mediastinal disorders | 2/3 | 0/6 | — | — | 0/15 | 0/4 |
| ConstipationGastrointestinal disorders | 1/3 | 3/6 | — | — | 2/15 | 0/4 |
Subjects were not enrolled into Cohort 2 and Cohort 3 as maximum tolerated dose was determined to be .5mg/m2.
| Age, Customized(Participants) | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort | Total |
|---|---|---|---|---|---|---|---|
| Age >/= 18yrs | 3 | 6 | — | — | 15 | 4 | 28 |
| Sex: Female, Male(Participants) | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort | Total |
|---|---|---|---|---|---|---|---|
| Female | 1 | 3 | — | — | 8 | 1 | 13 |
| Male | 2 | 3 | — | — | 7 | 3 | 15 |
| Race (NIH/OMB)(Participants) | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 3 | 6 | 0 | 0 | 15 | 4 | 28 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Escalation Phase Omacetaxine .75mg/m2 | Cohort 0: De-Escalation Omacetaxine .5mg/m2 | Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 | Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 | Cohort 4: Expansion Phase Omacetaxine .5mg/m2 | Cohort 5: Relapse Cohort | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 3 | 6 | 0 | 0 | 14 | 4 | 27 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in Oct 2025, 84 months.
Results were first posted in Sep 2026, 11 months after primary completion.
Of 68 non-industry phase 1/2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 72 months of starting (the median), counting those still running; a quarter within 49 and three quarters within 142. This study's 84 months is above that.
Counting every sponsor, half of 109 studies reached it within 78 months; a quarter within 49 and three quarters within 110.
How these figures are worked out, and which studies are left out of them.
Cohort 0: De-Escalation Omacetaxine .5mg/m2 · Cohort 1: Escalation Phase Omacetaxine .75mg/m2 · Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 · Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 · Cohort 4: Expansion Phase Omacetaxine .5mg/m2 · Cohort 5: Relapse Phase
Cohort 0: De-Escalation Omacetaxine .5mg/m2 · Cohort 1: Escalation Phase Omacetaxine .75mg/m2 · Cohort 2: Escalation Phase Omacetaxine 1.0mg/m2 · Cohort 3: Escalation Phase Omacetaxine 1.25mg/m2 · Cohort 4: Expansion Phase Omacetaxine .5mg/m2 · Cohort 5: Relapse Phase
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Homoharringtonine · Azacitidine
University of Colorado, Denver →